Gastroesophageal Reflux Clinical Trial
Official title:
Valvuloplasty as Alternative to Toupet Fundoplication for the Minimal Invasive Treatment of Gastroesophageal Reflux Disease: A Randomized Controlled Trial
This monocenter randomized controlled trial aims to compare postoperative outcomes of a laparoscopic valvuloplasty with a Toupet fundoplication in patients with GERD with a maximum hiatal hernia of 3cm. In addition, an economic evaluation of the new intervention will be done in order to determine cost-effectiveness and costs per quality-adjusted life-year (QALY).
This is a prospective, interventional, double-blinded, monocenter randomized controlled
trial comparing a laparoscopic gastroesophageal valvuloplasty to laparoscopic Toupet
fundoplication in patients with proven GERD with a maximum hiatal hernia of 3cm. In this
design, both patient and researcher are blinded to the treatment allocation.
Block randomization will be used to ensure an equal number in each treatment arm. Block
randomization works by randomizing participants within blocks such that an equal number are
assigned to each treatment. To reduce selection bias by predictability of the treatment
allocation, random block sizes are used. Also the investigator is kept blind to the size of
each block. A computer is used to generate 15 blocks for each participating center with
random block sizes of 4, 8 and 12. Allocation proceeds by randomly selecting one of the
orderings and assigning the next block of participants to study groups according to the
specified sequence.
Patients will be included during a two-year period and followed for a minimum of one year.
When a patient is referred to a participating surgeon for antireflux surgery, he or she will
receive study information to give them sufficient time for consideration. The surgeon will
ensure all required pre-operative diagnostic tests are performed and that the indication for
surgery is valid. During a follow-up visit, the surgeon ascertains that the patient complies
with all inclusion criteria and does not meet any of the exclusion criteria. Study
participation will be discussed and after informed consent is obtained, the patient will be
included in the trial.
After inclusion, the patient is immediately randomized but treatment allocation is not yet
shared with the surgeon. The patient will receive validated questionnaires to record the
pattern of symptoms, quality of life, medication and medical care usage. Data from the
pre-operative tests will be recorded.
On the day of surgery, the surgeon will be able to see treatment allocation and after
performing the appropriate surgical procedure, records the course and specifics of the
surgical procedure. Patients will receive a diary to record their meals and symptoms.
Follow-up in the outpatient clinic will take place at the surgeon's discretion. At fixed
moments: 3, 6 and 12 months after surgery, the patients will once more receive validated
questionnaires. Also at about three months, a follow-up manometry and 24-hour pH and/or
impedance monitoring will be performed.
A power analysis was performed to calculate the sample size. Our primary aim was to compare
the effect of both surgical procedures. Based upon the current medical literature, the
objective/subjective success rate for the laparoscopic Toupet fundoplication is around 88%.
Pilot data from a retrospective cohort of patients that underwent valvuloplasty report a
subjective success rate of 96%. Our hypothesis was that the gastroesophageal valvuloplasty
is not inferior to the Toupet fundoplication when comparing its effects on acid control.
To prove non-inferiority of the valvuloplasty regarding acid reflux control, using a
non-inferiority limit of 5%, 73 patients are required in each group. In all power
calculations, a significance of 5% and power of 90% was used.
To accommodate for a loss to follow-up of up to 10 percent, a total sample size of 160 was
chosen.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05561179 -
Hyaluronic Acid in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Completed |
NCT01946971 -
Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01825473 -
Study of Erythromycin in GER-Associated Apnea of the Newborn
|
N/A | |
Completed |
NCT00614536 -
Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period
|
Phase 4 | |
Completed |
NCT00365300 -
Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)
|
Phase 3 | |
Completed |
NCT00373997 -
Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux
|
Phase 4 | |
Completed |
NCT00284908 -
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00291746 -
Validation of RDQ Questionnaire
|
Phase 4 | |
Completed |
NCT00567021 -
German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms
|
N/A | |
Completed |
NCT01167543 -
Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease
|
N/A | |
Completed |
NCT00141960 -
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00215787 -
Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease
|
N/A | |
Completed |
NCT00226044 -
Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.
|
Phase 3 | |
Completed |
NCT01048840 -
Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age
|
||
Completed |
NCT00181805 -
Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents
|
||
Terminated |
NCT01281553 -
A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease
|
Phase 4 | |
Completed |
NCT05486169 -
Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy
|
N/A | |
Completed |
NCT04034017 -
Gastroesophageal Reflux Disease Among College Students
|
||
Terminated |
NCT03226054 -
Determining Risk Factors for Successful PPI Weaning
|
N/A |